Changing FDA Regulatory Environment Could Bolster Biotech, ‘BBH’

The Food & Drug Administration’s (FDA) recent green light of Biogen’s Alzheimer’s disease drug Aducanumab – the first new Alzheimer’s approval in roughly two decades – could be a sign the FDA is taking a new approach to approvals. That could benefit biotechnology stocks and exchange...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.